Study on compatibility rationality of Shufeng Jiedu Capsule based on network pharmacology / 中草药

ABSTRACT

Objective: To explore the compatibility rationality of Shufeng Jiedu Capsule (SJC) for the treatment of upper respiratory infection (URI). Methods: The potential targets and pathways of 32 compounds selected from ‘heat-clearing and detoxicating group’ (HCDG), ‘relieving exterior syndrome group’ (RESG), and ‘Glycyrrhiza uralensis group (GUG)’ of SJC were predicted by the methods of network pharmacology. The mechanism and compatibility rationality of SJC were analyzed by data integration and analysis. Results: The in silico prediction results showed that 32 compounds of SJC affected 34 related pathways through 94 target proteins which mainly involved with inflammation, lipopolysaccharide and bacterium response, immunoreaction and so on. The three groups of HCDG, RESG, and GUG not only showed common targets and pathways but also had their own emphasis to exert synergistic effects. Conclusion: HCDG plays a therapeutic role by intervening in related physiological process, such as inflammatory response, lipopolysaccharide and bacterium response, defense response and immune response. In addition to providing synergistic effects with HCDG, RESG can also intervene in the process of the sweating and antipyretic through multiple pathways. GUG showed auxiliary therapeutic effect by participating in processes of anti-inflammatory and enhancing the body immunity.